The Food and Drug Administration says it continues to monitor the cases of patients experiencing side effects while taking the anti-obesity drug Redux, but it says thus far there have been no unexpected findings.

"The data to date regarding Redux do not raise any red flags," agency spokesman Don McLearn said Monday.The agency's comment came after The Associated Press reported Friday that many scientists question why the government has let Redux sell so long without having the manufacturer, Wyeth-Ayerst Laboratories, study a possible brain-damaging side effect. The FDA approved Redux for sale a year ago, and that study is expected to begin soon, the agency says.